Therefore, the superior outcomes of ABCP in EGFR‐mutant NSCLC may be owing to increased sensitivity to bevacizumab, which effectively blocks VEGF‐mediated oncogenic signaling activation or reverses immune suppression [6]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.